Featured News

Our Partners

Latest News

OpenEvidence and Penn Medicine Partner to Extend AI Clinical Decision Support to Botswana

OpenEvidence and Penn Medicine announced a global partnership on September 15, 2026 to deploy OpenEvidence’s AI-powered clinical decision-making platform across Penn Medicine’s more than 10,000 clinicians, with plans to extend the tools to low- and middle-income countries through the 25-year-old Botswana-UPenn Partnership (BUP). Travis Zack, MD, PhD, Chief Medical Officer of OpenEvidence, framed the collaboration […]

Wayne’s PurpleLab Partners with Chalice AI to Turn Healthcare Data into Predictive Ad Targeting

PurpleLab, a health-tech company headquartered in Wayne, Pennsylvania, just outside Philadelphia, announced a partnership with Chalice AI on September 14, 2026 aimed at bringing predictive intelligence to healthcare advertising. Kyle Armstrong, PurpleLab’s VP of Agency and Platform Sales, tied the partnership’s value directly to that transparency: “AI is only as valuable as the data powering […]

Jazz Pharmaceuticals Completes $820 Million Acquisition of Actio Biosciences

Jazz Pharmaceuticals plc, the Dublin-headquartered biopharma with a major U.S. hub in Philadelphia, announced on September 15, 2026 that it completed its acquisition of Actio Biosciences, Inc. for an $820 million upfront payment, gaining Actio’s lead asset, ABS-1230. President and CEO Renee Gala said: “ABS-1230 holds the promise of being a transformative, first-in-class therapy for […]

New Hope’s Orchestra BioMed Receives $6.1 Million Milestone Payment from Vivasure-Haemonetics Deal

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO), the New Hope, Pennsylvania-based biomedical innovation company, announced on September 15, 2026 that it received a $6.1 million milestone payment on September 14 tied to Haemonetics Corporation’s (NYSE: HAE) acquisition of Vivasure Medical Limited, a company Orchestra BioMed has held a strategic stake in since its own formation. The […]

Freedom Mortgage’s Stanley Middleman Gives Penn Medicine a New Engine for Turning Research Into Treatments

Stanley C. Middleman, the Philadelphia-born founder and CEO of Freedom Mortgage — one of the nation’s largest mortgage lenders and a leading Ginnie Mae servicer and VA and FHA lender, focused on expanding homeownership for military families, veterans, first-time homebuyers, and underserved communities — announced a transformational gift to Penn Medicine on September 10, 2026 […]

13 Life Sciences & Healthcare Companies From Greater Philadelphia Made Newsweek’s “America’s Greatest Companies 2026” List

Newsweek and Plant-A Insights Group recently released America’s Greatest Companies 2026, Newsweek’s America’s Greatest Companies 2026 recognizes U.S. organizations that stand out for more than financial performance. The ranking evaluates companies across key measures including financial strength, workforce sentiment, innovation and sustainability, highlighting businesses demonstrating resilience, responsible leadership and long-term growth. The 2026 list features […]

People on the Move: Ingrid Zhang Named Chief Executive Officer of Legend Biotech

Legend Biotech has appointed Ingrid Zhang as Chief Executive Officer, effective September 15, 2026, succeeding Alan Bash, who served as Interim CEO. “Following a comprehensive search process, the Board concluded that Ingrid is the right leader to guide Legend Biotech through its next phase of growth,” said Frank Zhang, EMBA, PhD, Chairman of the Board. […]

Buzzin’ Brood Spotlight: Jonathan Baddoo, Loyola University Maryland

BioBuzz’s Buzzin’ Brood Student Spotlight series celebrates the upcoming generation of life sciences talent — and the programs, institutions, and organizations investing in them. Name: Jonathan Baddoo Hometown: Upper Marlboro, Maryland Institution: Loyola University Maryland (Baltimore, Maryland) Role: Bio-Health Student, Concentration in Biological Commercialization Jonathan Baddoo is a Bio-Health student, a Model UN delegate, and […]

Elvinix Licenses Zealand Pharma’s Dual-Agonist Peptide Portfolio to Chase a Disease-Modifying Therapy for Type 1 Diabetes

Elvinix Inc., a Dover, Delaware-based biopharmaceutical company developing regenerative therapy for type 1 diabetes (T1D), announced on September 15, 2026 an exclusive license agreement with Zealand Pharma A/S for Zealand’s GLP-1/gastrin dual-agonist peptide portfolio, along with the accompanying preclinical data package.  CEO Daniil Koshelev said: “This license gives us a peptide platform backed by years […]